Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 3.76% and Operating profit at 4.45% over the last 5 years
2
The company declared negative results in Mar'25 after positive results in Dec'24
3
With ROE of 12.29%, it has a very expensive valuation with a 8.72 Price to Book Value
4
Majority shareholders : Non Institution
Stock DNA
Pharmaceuticals & Biotechnology
CNY 370,781 Million (Large Cap)
71.00
NA
0.34%
-0.68
12.30%
6.23
Revenue and Profits:
Net Sales:
7,427 Million
(Quarterly Results - Sep 2025)
Net Profit:
1,306 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.83%
0%
-9.83%
6 Months
-23.33%
0%
-23.33%
1 Year
19.43%
0%
19.43%
2 Years
26.39%
0%
26.39%
3 Years
27.96%
0%
27.96%
4 Years
39.67%
0%
39.67%
5 Years
-33.53%
0%
-33.53%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.76%
EBIT Growth (5y)
4.45%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.57
Tax Ratio
12.26%
Dividend Payout Ratio
18.49%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
99,562.58%
ROE (avg)
135,472.87%
Valuation key factors
Factor
Value
P/E Ratio
71
Industry P/E
Price to Book Value
8.72
EV to EBIT
62.58
EV to EBITDA
55.89
EV to Capital Employed
20.86
EV to Sales
15.88
PEG Ratio
2.21
Dividend Yield
0.25%
ROCE (Latest)
33.33%
ROE (Latest)
12.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
7,426.90
8,555.60
-13.19%
Operating Profit (PBDIT) excl Other Income
1,285.00
2,854.70
-54.99%
Interest
0.70
0.70
Exceptional Items
-13.50
124.40
-110.85%
Consolidate Net Profit
1,305.60
2,578.20
-49.36%
Operating Profit Margin (Excl OI)
173.00%
306.70%
-13.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -13.19% vs 18.74% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -49.36% vs 37.40% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
27,787.80
22,646.60
22.70%
Operating Profit (PBDIT) excl Other Income
7,271.20
4,901.20
48.36%
Interest
6.50
6.70
-2.99%
Exceptional Items
108.60
-128.30
184.65%
Consolidate Net Profit
6,337.00
4,277.80
48.14%
Operating Profit Margin (Excl OI)
230.30%
181.40%
4.89%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 22.70% vs 7.22% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 48.14% vs 12.13% in Dec 2023
About Jiangsu Hengrui Pharmaceuticals Co., Ltd. 
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






